Features | Partner Sites | Information | LinkXpress
Sign In
Demo Company

Monoclonal Antibody Blocks Pro-Life Molecular Signaling in Pancreatic Tumors

By BiotechDaily International staff writers
Posted on 29 Jul 2013
 Image: CTGF biology (Photo courtesy of Fibrogen, Inc).
Image: CTGF biology (Photo courtesy of Fibrogen, Inc).
A monoclonal antibody that selectively binds to connective tissue growth factor (CTGF) slows the progress of pancreatic tumors by decreasing the activity of XIAP (X-linked inhibitor of apoptosis), a protein that promotes cancer cell survival.

CTGF causes a variety of cellular responses including reduced cell adhesion and enhanced cell migration and proliferation. CTGF has also been shown to be essential for epithelial to mesenchymal transition (EMT), a process whereby normal functioning cells morph into ones that produce mainly scar tissue (of which collagen in the major protein component). Cellular responses to CTGF also have effects at the tissue level including remodeling, formation of new blood vessels (angiogenesis), changes in blood vessel architecture (permeability and stiffness), and replacement of normal tissue with scar tissue.

Treatment of pancreatic ductal adenocarcinoma (PDA) is hampered by poor tissue perfusion that restricts the amount of drug able to reach the tumor. Furthermore, cells in the tumor microenvironment produce molecules, such as CTGF, that provide "pro-life" cues that promote drug resistance in the cancer cells.

Investigators at Cold Spring Harbor Laboratory (NY, USA) used a mouse pancreatic cancer model to study the impact on tumor growth caused by the interaction between CTGF and Fibrogen Inc.'s (San Francisco, CA, USA) CTGF-specific monoclonal antibody, FG-3019.

They reported in the July 8, 2013, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS) that pancreatic tumors in mice treated with FG-3019 in combination with the chemotherapeutic drug gemcitabine stopped growing. The response to FG-3019 correlated with the decreased expression of a previously described promoter of chemotherapy resistance, the X-linked inhibitor of apoptosis protein.

"In addition to drug delivery being a problem, there is also this nurturing aspect that prevents cancer cells responding to the drugs," said senior author Dr. David A. Tuveson, professor of medical oncology at Cold Spring Harbor Laboratory. "Both CTGF and XIAP have been shown to be present in human pancreatic cancer tumors so combination therapy using antagonists of either molecule could be a feasible approach."

Related Links:

Cold Spring Harbor Laboratory
Fibrogen Inc.


Drug Discovery

view channel
Image: Endoscopic image of a bowel section known as the sigmoid colon afflicted with ulcerative colitis. The internal surface of the colon is blotchy and broken in places (Photo courtesy of Wikimedia Commons).

Orally Delivered Curcumin-Loaded Microparticles Effectively Treat Mouse Model of Ulcerative Colitis

Microparticles (MPs) loaded with the efficient anti-inflammatory agent curcumin were found to effectively treat a mouse model of ulcerative colitis. Ulcerative colitis is a chronic relapsing disease... Read more

Lab Technologies

view channel

New Genomic Research Kit Simplifies Exome Studies

An exciting new tool is now available for biotech researchers working in the field of genomic analysis. The human exome is critical to our genetic make-up and is generally accepted as having the greatest influence on how the genetic blueprint is utilized. The exome is defined as all coding exons in the genome and is... Read more


view channel

Collaboration Agreement to Boost Discovery of Fully Human Antibodies for Therapeutic Use

The discovery of fully human antibodies for therapeutic use will be boosted by a recently announced collaboration between a major university research center and a dynamic biopharmaceutical development company. Regeneron Pharmaceuticals, Inc. (Tarrytown, New York, USA) and The Experimental Therapeutics Institute (ETI)... Read more


17 Oct 2015 - 21 Oct 2015
25 Oct 2015 - 29 Oct 2015
16 Nov 2015 - 19 Nov 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.